Memphasys Limited
Research Memphasys Limited (MEM.AX) on Bullrun: market cap AUD 12.38M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMEM.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryMedical Devices
- CurrencyAUD
- Market capAUD 12.38M
- Financial periodFY2025
Valuation Snapshot
latest market cap is AUD 12.38M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | 0 | n/a | n/a | n/a |
| FY2024 | AUD 60.00K | -AUD 4.44M | -AUD 3.87M | 2.7% | 0 | AUD 277.80K | AUD 4.81M | AUD 6.84M |
| FY2023 | AUD 15.37K | -AUD 3.40M | -AUD 3.23M | 60.0% | 0 | AUD 637.83K | AUD 6.37M | AUD 7.38M |
| FY2022 | AUD 27.15K | -AUD 2.08M | -AUD 2.61M | 30.4% | 0 | AUD 269.08K | AUD 5.56M | AUD 7.65M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 12.38M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Memphasys Limited
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Memphasys Limited's market cap?
Memphasys Limited's market capitalization is AUD 12.38M.
What does Memphasys Limited do?
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals.